Harte-Hanks revamps digital practice

Share this article:
Harte-Hanks' Glen Hartman
Harte-Hanks' Glen Hartman

Harte-Hanks has announced a series of changes and promotions as it enhances its digital practice area.

Glen Hartman has been promoted to managing director of the digital practice.

Previously, Hartman led Harte-Hanks as an SVP for digital marketing for data-based marketing solutions. In his new role, Hartman is responsible for managing all aspects of the digital practice and its offerings including web site development, online advertising, search engine marketing, e-mail, mobile messaging, Web analytics and social networking.

In addition, the digital practice has added to its management team with several new hires. These hires include Julie Donovan, VP/practice leader, digital media; Thomas Molitor, VP/practice leader, digital interaction; Gary Druckenmiller Jr., VP, strategy & business development, digital practice.

“The Harte-Hanks digital practice has grown considerably throughout the past year,” Frank Harvey, corporate officer and VP said in a statement. “While this growth represents the increasing importance of digital media and marketing, it also represents the value of our digital expertise including the understanding we provide to our clients about how digital applications and their successful executions feed a larger multichannel strategy.”

Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...